Frequent Links

cancer product Neuronal cells Journals thermostable enzymes Top journals in glycomics & lipidomics flavanoids radiology and biomechanics Bone Marrow Stem Cells Research Articles Palliative Care Medicine Review Articles marine-sponges-Scholarly journal Herbal Medicine - Impact factor Scholarly Pharmacovigilance & Clinical Trials Journals Physiotherapy Online Journals Oryza sativa Immunization Coverage Specialist-tourism-Scholarly-journal

Open Access Articles- Top Results for Farletuzumab

Farletuzumab

</th></tr>

Farletuzumab^?
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	FR-alpha
Clinical data
Identifiers
CAS Registry Number	896723-44-7^7pxN
ATC code	None
UNII	2O09BG0OWA^7pxY
KEGG	D09343^7pxY
Chemical data
Formula	C₆₄₆₆H₉₉₂₈N₁₇₁₆O₂₀₂₀S₄₂
Molecular mass	145.4 kDa
14pxN (what is this?) (verify)

Farletuzumab (MORAb-003) is a monoclonal antibody^[1] which is being investigated for the treatment of ovarian cancer.^[2]^[3]

This drug was developed by Morphotek, Inc.

It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.

References

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
^ ClinicalTrials.gov: Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
^ ClinicalTrials.gov: Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Ontuxizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Index of neoplasms and cancer

Description	Tumor suppressing and oncogenes Tumor markers Carcinogen

Disease	Neoplasms and cancer Symptoms and signs Paraneoplastic

Treatment	Radiotherapy Drugs Immunotherapy intracellular chemotherapeutics extracellular chemotherapeutics adjuvant detoxification

Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.

Search

Actions

Journals

Adverts

Frequent Links

Open Access Articles- Top Results for Farletuzumab

Farletuzumab

References